452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count

Background

Cancer is the leading cause of death worldwide. In 2012, around 8,2 million deaths were caused by cancer.¹ Chemotherapy in cancer patients is often accompanied by bone marrow aplasia which manifests as anemia. The choice of therapy for anemia in cancer patients are blood transfusions. In addition, an Erythropoiesis-Stimulating Agent (ESA) can be added which can increase the production of erythrocytes in the bone marrow.^17,18 Increased erythropoeisis process induced by ESA will bind to Erythropoietin Receptor (EpoR) on the erythropoetic cell surface in the bone marrow. In other hand, ESA therapy were still not giving a satisfied result and still lack of data about expression of EpoR. Absolute reticulocyte count (ARC) is a marker of erythrocyte production that is more accurate in distinguishing hypo or hyperproliferative anemia.

Methods

This study was an observational analytic, cross sectional study carried out at the hematology specialty clinic, integrated oncology unit, Department of Internal Medicine, Dr. M. Djamil Padang Hospital for 6 months. A sample of 30 patients who met the inclusion and exclusion criteria. Initial screening for potential subjects was carried out, the research protocol was explained and informed consent was requested.

Results

There is a decrease of EpoR expression (8481,33±5364,46 copies/uL) compared to normal value (34-3000 x 10³ copies/uL). There is also a decrease of ARC (27,97±9,24 x10⁹/L) compared to normal value (50-100 x10⁹/L). Positive correlation was found between EpoR expression and ARC. In the statistical test using the Pearson test it was found that the correlation was significant (p < 0.05) with very strong gradations (r = 0.819).

Conclusions

There is a decrease the average of EpoR expression in patient with anemia related chemotherapy and significant positive correlation with a very strong gradation between EpoR expression and ACR .

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Division of Hematology and Medical Oncology, Internal Medicine Department, Dr. M. Djamil General Hospital, Padang, Indonesia.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.